Core Insights - Teknova and Pluristyx have announced a collaboration to produce and commercialize the PluriFreeze™ cryopreservation system, aimed at enhancing the development of allogeneic cell therapies [1][2] - Teknova will serve as the exclusive manufacturer and distributor of the PluriFreeze product line in the United States and Canada, facilitating wider access for customers [2][3] Company Overview - Teknova specializes in manufacturing critical reagents for the life sciences industry, supporting the discovery and development of novel therapies, vaccines, and diagnostics [5] - Pluristyx focuses on providing induced Pluripotent Stem Cells (iPSCs) and innovative technologies to accelerate the development lifecycle of cell therapies [6][7] Product Details - The PluriFreeze system includes a protective wash and a low viscosity freezing medium, designed to streamline the manufacturing process of cell products [3][4] - PluriFreeze Base mimics intracellular space and provides metabolic support, while PluriFreeze PF10 contains 10% dimethyl sulfoxide (DMSO) to simplify scale-up and automation [3] Future Developments - Additional information regarding pricing and availability of the PluriFreeze products will be disclosed at the BioProcess International West conference in San Diego, starting March 19, 2025 [4]
Teknova and Pluristyx Announce Collaboration to Streamline the Manufacture of Next-Generation Cell Therapies